187 related articles for article (PubMed ID: 24002763)
1. Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.
Kang CY; Wang J; Axell-House D; Soni P; Chu ML; Chipitsyna G; Sarosiek K; Sendecki J; Hyslop T; Al-Zoubi M; Yeo CJ; Arafat HA
J Gastrointest Surg; 2014 Jan; 18(1):7-15. PubMed ID: 24002763
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer.
Arafat H; Lazar M; Salem K; Chipitsyna G; Gong Q; Pan TC; Zhang RZ; Yeo CJ; Chu ML
Surgery; 2011 Aug; 150(2):306-15. PubMed ID: 21719059
[TBL] [Abstract][Full Text] [Related]
3. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
4. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
5. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
[TBL] [Abstract][Full Text] [Related]
6. Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.
Huang T; Jiang SW; Qin L; Senkowski C; Lyle C; Terry K; Brower S; Chen H; Glasgow W; Wei Y; Li J
Int J Mol Sci; 2015 Jan; 16(2):2956-70. PubMed ID: 25642754
[TBL] [Abstract][Full Text] [Related]
7. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
8. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
9. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
Joergensen MT; Brünner N; De Muckadell OB
Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
[TBL] [Abstract][Full Text] [Related]
10. Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation of sterol regulatory element binding protein-1 and activation of acetyl CoA carboxylase.
Al-Zoubi M; Chipitsyna G; Saxena S; Sarosiek K; Gandhi A; Kang CY; Relles D; Andrelsendecki J; Hyslop T; Yeo CJ; Arafat HA
J Gastrointest Surg; 2014 Feb; 18(2):257-68; discussion 268. PubMed ID: 24091913
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
12. Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics.
Qiao J; Fang CY; Chen SX; Wang XQ; Cui SJ; Liu XH; Jiang YH; Wang J; Zhang Y; Yang PY; Liu F
Oncotarget; 2015 Oct; 6(30):29929-46. PubMed ID: 26338966
[TBL] [Abstract][Full Text] [Related]
13. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
14. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
[TBL] [Abstract][Full Text] [Related]
16. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL
Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
19. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of cytochrome P450 omega-hydroxylase isoforms and their association with clinicopathological features in pancreatic ductal adenocarcinoma.
Gandhi AV; Saxena S; Relles D; Sarosiek K; Kang CY; Chipitsyna G; Sendecki JA; Yeo CJ; Arafat HA
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S636-43. PubMed ID: 23846787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
